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Abstract Neuropathic pain that typically develops when
peripheral nerves are damaged through surgery, bone
compression in cancer, diabetes, or infection is a major
factor causing impaired quality of life in millions of people
worldwide. Recently, there has been a rapidly growing
body of evidence indicating that spinal glia play a critical
role in the pathogenesis of neuropathic pain. Accumulating
findings also indicate that nucleotides play an important
role in neuron-glia communication through P2 purinocep-
tors. Damaged neurons release or leak nucleotides includ-
ing ATP and UTP to stimulate microglia through P2
purinoceptors expressing on microglia. It was shown in an
animal model of neuropathic pain that microglial P2X4 and
P2X7 receptors are crucial in pain signaling after peripheral
nerve lesion. In this review, we describe the modification of
neuropathic pain sensation through microglial P2X4 and
P2X7, with the possibility of P2Y6 and P2Y12 involvement.
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Abbreviations
ADP adenosine 5′-diphosphate
ATP adenosine 5′-triphosphate
BDNF brain-derived neurotrophic factor
BzATP 2′- and 3′-O-(4-benzoylbenzoyl) adenosine
5′-triphosphate
[Ca
2+]i intracellular Ca
2+ concentration
CNS central nervous system
CR3 complement receptor 3
IL-1β interleukin-1β
IL-6 interleukin-6
OATP oxidized ATP
PK11195 [1-(2-chlorophenyl)-N-methyl-N-(1-methyl-
propyl)-3-isoquinolineiso-quinoline
carboxamide]
PPADS pyridoxalphosphate-6-azophenyl-2′,
4′-disulphonic acid
TNP-ATP 2′,3′-O-(2,4,6-trinitrophenyl)adenosine
5′-triphosphate
TNF-α tumor necrosis factor-α
UDP uridine 5′-diphosphate
IL-1β interleukin-1β
Introduction
There is a type of pain that does not go away even though
the tissue has already healed. One type of this pain is called
neuropathic pain that typically develops when peripheral
nerves are damaged such as through surgery, bone
compression in cancer, diabetes, or infection. Neuropathic
pain is a major factor causing impaired quality of life in
millions of people worldwide and is frequently resistant to
all known analgesic drugs. Over the last decade, accumu-
lating evidence concerning how peripheral nerve injury
creates neuropathic pain has suggested that nerve injury
produces molecular and cellular alterations that result in
multiple forms of neuronal plasticity and anatomical
reorganization in the dorsal horn of the spinal cord. These
alterations have been proposed to be crucial in the
pathogenesis of neuropathic pain [1, 2]. While the dominant
theme in research on neuropathic pain has been to
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system and the dorsal horn, there is a rapidly growing body
of evidence indicating that spinal glial cells play a critical
role in the pathogenesis of neuropathic pain.
Recently, growing evidence has indicated that neuron-
glia interaction is a key idea to understand functions of the
central nervous system (CNS). Especially glia play impor-
tant roles in pathophysiological situations of the CNS
including psychiatric disorders, physical trauma, and
infections [3]. Glia consist of three members: astrocytes,
oligodendrocytes, and microglia. Accumulating findings
also indicate that nucleotides play an important role in
neuron-glia communication through P2 purinoceptors, even
though ATP is recognized primarily to be a source of free
energy and nucleotides are key molecules in cells. Micro-
glia, which are thought to be residential macrophages in the
CNS, express P2 purinoceptors, mainly P2X4 and P2X7 as
well as P2Y2, P2Y6, and P2Y12 [4]. Damaged neurons
release or leak nucleotides including ATP and UTP to
stimulate microglia [5, 6]. It is clear that these nucleotides
trigger the release of various neurotoxic and neuroprotec-
tive cytokines and growth factors via different purine
receptors [4, 7] or induce P2Y12-dependent chemotaxis in
cultured cells [8, 9]. It was shown in an animal model of
neuropathic pain that microglial P2X4 and P2X7 receptors
are crucial in pain signaling after peripheral nerve lesion
[10–12]. Other purine receptors are upregulated in micro-
glia in response to neuronal injury, as was recently
demonstrated for P2Y6 [6]. The P2Y6 receptor triggers
microglial phagocytosis [6]. In this paper, we review the
modification of pain sensation through microglial P2X4 and
P2X7, and also point out the possibility of P2Y6 and P2Y12
involvement in pain signaling.
P2X4 in neuropathic pain
We found that the marked tactile allodynia that develops
following nerve injury was reversed by acutely administer-
ing TNP-ATP intrathecally but was unaffected by admin-
istering PPADS [10]. From the pharmacological profiles of
TNP-ATP (blocking P2X4 at high concentration) and
PPADS (not blocking P2X4), it was suggested that tactile
allodynia depends upon P2X4 in the spinal cord. The
expression of P2X4 protein, normally low in the naïve
spinal cord, progressively increased in the days following
nerve injury with a time course parallel to that of the
development of tactile allodynia. Double immunolabeling
analysis demonstrated that not neurons or astrocytes but
activated microglia in the dorsal horn were intensely
positive for P2X4 protein [10]. Moreover, intrathecally
administered antisense oligodeoxynucleotide for P2X4R
reduced the expression of P2X4 protein in spinal microglia
and prevented the development of the nerve injury-induced
tactile allodynia. In naïve rats, intrathecal administration of
cultured microglia that were preincubated with ATP to
activate P2X4 produced tactile allodynia over the 3–5h
after the administration [10].
Since it was already reported that the nerve injury-
induced tactile allodynia depends on a depolarizing shift in
the Eanion of spinal lamina I (LI) neurons in the dorsal
spinal cord, resulting in converting the GABAA receptor-
and glycine receptor-mediated inhibition to excitation [13],
it was considered that microglia may affect Eanion in LI
neurons. To investigate this possibility, microglia were
administered to the lumbar spinal level of naïve rats by an
intrathecal catheter as described [11]. Administering micro-
glia stimulated with ATP caused a progressive tactile
allodynia over the 5 h after injection. Eanion in LI neurons
from rats administered ATP-stimulated microglia was
shifted to −61.6 mV from −68.3 mV of normal rats. In
addition, we found that GABA response switched from
hyperpolarizing in control rats to depolarizing in microglia-
treated rats. Activated microglia secrete various biologically
active molecules, one of which, BDNF, was implicated in
the hypersensitivity of dorsal horn neurons that follows
sensitization and inflammation [14–16] and in anion
gradient shifts in the hippocampus [17]. Indeed, intrathecal
administration of recombinant BDNF produced tactile
allodynia comparable to that produced by ATP-stimulated
microglia [11]. Eanion of LI neurons in slices treated with
BDNF (>90 min, in vitro) was significantly less negative
than that of LI neurons from control slices. The rise in [Ca
2+]i
was prevented by the GABAA receptor blocker bicuculline,
confirming that the effect was mediated by GABAA
receptors. Thus, acute administration of BDNF in slices
caused a depolarizing shift in Eanion and caused GABA to
produce net excitation [11]. Moreover, a function-blocking
antibody against the TrkB receptor (anti-TrkB) and a BDNF-
sequestering fusion protein (TrkB-Fc) acutely inhibited the
allodynia and the shift of Eanion of LI neurons [11]. The
administration of ATP-stimulated microglia with either anti-
TrkB or TrkB-Fc did not develop tactile allodynia. After
pretreatment of microglia with double-stranded short interfer-
ing RNA directed against BDNF (BDNF siRNA), the ATP-
stimulated microglia injected intrathecally into normal rats
did not cause the allodynia [11]. Anti-TrkB and BDNF
siRNA prevented the shift in Eanion induced by ATP-
stimulated microglia. ATP stimulation caused release of
BDNF from microglia in culture. This effect of ATP was
blocked by treating the cultures with the P2X receptor
blocker TNP-ATP. In addition, pretreatment of the microglia
with BDNF siRNA prevented release of BDNF by ATP
stimulation. By bath application of TNP-ATP to spinal slices
taken from allodynic rats 2 weeks after nerve injury, Eanion of
LI neurons was returned to normal value [11]. These findings
312 Purinergic Signalling (2007) 3:311–316indicate that P2X4-dependent release of BDNF from micro-
glia is necessary to sustain both the tactile allodynia and the
depolarizing shift in Eanion in LI neurons that result from
nerve injury (Fig. 1).
P2X7 in neuropathic pain
P2X7 purinoceptors are a ligand-gated nonselective cationic
channel and are expressed predominantly on immune cells
[18]. Stimulation of the P2X7 receptors on microglia is
associated with release of cytokines including tumor
necrosis factor-α (TNF-α)[ 5, 19], interleukin-6 (IL-6)
[20], and interleukin-1β (IL-1β)[ 21–23]. Several cytokines
such as IL-1β, IL-6, and TNF-α in the dorsal horn are
increased after nerve lesion [24–26] and have been
implicated in contributing to neuropathic pain [24–27].
Recent evidence indicates the relationship between TNF-α
and neuropathic pain [28–32], and TNF-α released after
injury is proposed as an initiator of abnormal pain
sensation. TNF-α is upregulated after nerve injury in both
dorsal root ganglion (DRG) and spinal cord [33]. The
inhibition of TNF-α reduces the hyperalgesia in neuropathic
pain models [34]. Recent evidence indicates the relationship
between inflammatory cytokines including IL-1β and
neuropathic pain [25, 26, 28]. The expression of IL-1β is
upregulated in the spinal cord of several rat neuropathy
models [24–26]. These findings further support a role for
central IL-1β in the development and maintenance of
neuropathic pain through induction of a proinflammatory
cytokine cascade (Fig. 1).
Recently, it was reported that in mice lacking P2X7
inflammatory and neuropathic hypersensitivity is complete-
ly absent to both mechanical and thermal stimuli, whilst
normal nociceptive processing is preserved [12]. Contribu-
tion of P2X7 receptor to neuropathic pain is also demon-
Fig. 1 Schematic illustration of potential mechanisms by which P2X/
Y receptors in activated microglia modulate neuropathic pain signaling
in the dorsal horn. Activated microglia in the spinal cord after nerve
injury express ionotropic ATP receptors [e.g., P2X4 receptor (P2X4R)
or P2X7R]. P2X4R or P2X7R activation leads to the release of
bioactive diffusible factors such as BDNF and other proinflammatory
factors (cytokines and chemokines). BDNF causes a collapse of
transmembrane anion gradient in dorsal horn lamina I neurons
presumably through the downregulation of KCC2, which in turn
renders GABA and glycine effects depolarizing, rather than hyper-
polarizing, in these neurons. Microglial factors may also interact with
excitatory synapses of neighboring dorsal horn neurons and enhance
the excitability in dorsal horn neurons. The net hyperexcitability in the
dorsal horn pain network by these factors from activated microglia
may be responsible for neuropathic pain. Microglia also express G
protein-coupled ATP receptors [e.g., P2Y6 receptor (P2Y6R) and
P2Y12R]. Activating P2Y12R and P2Y6R leads to chemotaxis and
phagocytosis, respectively, but their functional relevance to neuro-
pathic pain remained to be determined
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for P2X7 receptor A-740003 [35]. The knockout animals
were unimpaired in their ability to produce mRNA for pro-
IL-1β, and cytometric analysis of paw and systemic
cytokines from knockout and wild-type animals following
adjuvant insult suggested a selective effect of the gene
deletion on release of IL-1β and IL-10, with systemic
reductions in adjuvant-induced increases in IL-6 and
MCP-1. In addition, P2X7 receptors were upregulated in
human dorsal root ganglia and injured nerves obtained from
chronic neuropathic pain patients [12]. It was hypothesized
that the P2X7 receptor plays a common upstream transduc-
tional role in the development of pain of neuropathic and
inflammatory origin via regulation of mature IL-1β
production.
In addition, a recent study has shown that activation of
P2X7 receptors expressed on satellite glia that enwrap each
DRG neuron leads to a release of TNF-α, which in turn
increases the excitability of DRG neurons [36]. P2X7
receptors are upregulated in surrounding satellite glial cells
in the DRG in humans [12]. Implication of TNF-α has been
reported in neuropathic pain [28–32]. Therefore, the
contribution of P2X7 receptor to neuropathic pain might
be related not only to the activation of microglial P2X7
receptors, but also to P2X7 receptors on other cell types
such as satellite glia.
P2Y6 and P2Y12 in neuropathic pain?
When neurons are injured or dead, microglia are activated,
resulting in their interaction with immune cells, active
migration to the site of injury, release of proinflammatory
substances, and the phagocytosis of damaged cells or
debris. For such activation of microglial motilities, extra-
cellular nucleotides have a central role. Extracellular ATP
functions as a chemoattractant. Microglial chemotaxis by
ATP via P2Y12 receptors was originally found by Honda
et al. [8] and has recently been confirmed in vivo in P2Y12
receptor knockout animals [37]. Neuronal injury results in
the release or leakage of ATP that appears to be a “find-me”
signal from damaged neurons to microglia to cause
chemotaxis. In addition to microglial migration by ATP,
another nucleotide, UDP, an endogenous agonist of the
P2Y6 receptor, greatly activates the motility of microglia
and orders microglia to eat damaged neurons. UDP does
not cause chemotaxis, but instead causes phagocytosis by
microglia [6]. Phagocytosis, a specialized form of endocy-
tosis, is the uptake by the cell of relatively large particles
(>1.0 μm) into vacuoles and has a central role in tissue
remodeling, inflammation, and the defense against infec-
tious agents [38]. Phagocytosis is initiated by the activation
of various cell surface phagocytosis receptors, including Fc
receptors, complement receptors, integrins, endotoxin recep-
tors (CD18, CD14), mannose receptors, and scavenger
receptors [39], which are activated by corresponding
extracellular ligands. In the CNS, a full innate immune
system, i.e., Fc receptors, complement system, scavenger
receptors, and Toll-like receptors etc., has been described,
and microglia reveal related roles as dedicated phagocytes.
Since recognition is the first and the most important step for
phagocytosis, extensive studies on phagocytosis receptors
have been reported. It is well-known that dying cells express
so-called eat-me signals such as phosphatidylserine on their
surface membrane [39], by which microglia recognize the
apoptotic cells to catch and remove them [39]. We first found
that exogenously applied UDP caused microglial phagocy-
tosis in a concentration-dependent manner, which was P2Y6
receptor-dependent. We found that neuronal injury caused by
kainic acid (KA) upregulated P2Y6 receptors in microglia,
the KA-evoked neuronal injury resulted in an increase in
extracellular UTP, which was immediately metabolized into
UDP in vivo and in vitro. Moreover, UDP leaked from
injured neurons caused P2Y6 receptor-dependent phagocy-
tosis in vivo and in vitro. These results suggest that UDP
could be a molecule that signals the crisis of damaged
neurons to microglia, triggering phagocytosis. It should be
noted that nucleotides could be both “find-me” and “eat-me”
signals. Cells release ATP, and we also found that KA caused
an increase in extracellular UTP/UDP. Therefore microglia
might be attracted by ATP/ADP [8, 40, 41] and subsequently
recognize UDP, leading to the removal of the dying cells and
their debris.
Are P2Y6 and P2Y12 receptors involved in neuropathic
pain? For this question, there is a report indicating that the
UDP-sensitive P2Y6 receptor produces inhibitory effects on
spinal pain transmission in a neuropathic pain model [42]. In
the neuropathic pain model, in which the sciatic nerves of rats
were partially ligated, UDP (30 and 100 nmol/rat) produced
significant antiallodynic effects. UDP (100 nmol/rat) caused
no motor deficit in the inclined plane test [42]. The
mechanism of this UDP-evoked inhibitory effect on neuro-
pathic pain is unknown. There is no evidence to show the site
(neuron or glia) of action of UDP. We are now investigating
the involvement of P2Y12 in pain signaling and have obtained
evidence suggesting the role of P2Y12 in the neuropathic pain
state.
Conclusion
Neuropathic pain is a major factor causing impaired quality
of life in millions of people worldwide. We have to try to
reveal the mechanism of this pain in order to develop
effective drugs against the pain. Recently, there has been a
314 Purinergic Signalling (2007) 3:311–316rapidly growing body of evidence indicating that spinal glia,
especially microglia, play a critical role in the pathogenesis
of neuropathic pain and that nucleotides play an important
role in neuron-glia communication through P2 purinocep-
tors. We described the modification of neuropathic pain
signaling through microglial P2X4 and P2X7, with the
possibility of P2Y6 and P2Y12 involvement (Fig. 1). It was
shown in an animal model of neuropathic pain that
microglial P2X4 and P2X7 receptors are crucial in pain
signaling after peripheral nerve lesion. Microglial P2Y6 and
P2Y12 play very interesting roles for phagocytosis and
chemotaxis, respectively. Besides, there is a possibility that
these receptors are involved in pain sensation. Additional
experiments are needed to clarify the possibility.
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